Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17638031 | 1.00 | KMT2A (0.48) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16925933 | 0.92 | KDM4E (0.45) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16925714 | 0.92 | KDM4E (0.45) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17637987 | 0.92 | KDM4E (0.42) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17637986 | 0.92 | KDM4E (0.42) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19472195 | 0.91 | NPC1 (0.45) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16801953 | 0.91 | L3MBTL1 (0.46) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17637912 | 0.91 | L3MBTL1 (0.46) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17637778 | 0.91 | NPSR1 (0.47) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17637885 | 0.91 | L3MBTL1 (0.46) | KMT2AMAPK1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197887-B1 | HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-10377766-B2 | Heterocyclic compounds with benzo(c)coumarin-structures | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2017-10-19 | — | — | US | disclosed |
| WO-2016045769-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | NISCH, SIRT3, NQO1 | KMT2A 3494/4885MAPK1 2068/4885NPC1 1598/4885 |
| US-10377766-B2 | Heterocyclic compounds with benzo(c)coumarin-structures | NISCH, SIRT3, NQO1 | KMT2A 3494/4885MAPK1 2068/4885NPC1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.